Safety and tolerability profile of the adenosine A2A receptor antagonist BIIB014 in Parkinson's disease: Pooled analysis of two placebo-controlled 8-week studies

被引：0
|
作者：
Papapetropoulos, S.
Borgohain, R.
Kellet, M.
Giladi, N.
Tomic, D.
Coppell, A.
Zhu, Y.
Barnard, J.
Miller, L.
O'Neill, G. N.
机构：
来源：
MOVEMENT DISORDERS | 2010年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
367
引用
收藏
页码：S304 / S304
页数：1
相关论文
共 50 条
  • [31] TWO-YEAR, PLACEBO-CONTROLLED SAFETY AND TOLERABILITY DATA FOR SAFINAMIDE AS ADD-ON TO L-DOPA IN PATIENTS WITH PARKINSON'S DISEASE
    Meshram, C.
    Borgohain, R.
    Bhatt, M.
    Chirileanu, D.
    Stocchi, F.
    Lucini, V.
    Giuliani, R.
    Anand, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 232 - 233
  • [32] Safety and Tolerability of Empagliflozin in Patients with T2D and Advanced Kidney Disease: A Large, Pooled Analysis of Placebo-Controlled Clinical Trials
    Levin, Adeera
    Nangaku, Masaomi
    Kadowaki, Takashi
    Tuttle, Katherine R.
    Hauske, Sibylle Jenny
    Zeller, Cordula
    Kohler, Sven
    Von Eynatten, Maximilian
    Wanner, Christoph
    DIABETES, 2017, 66 : A325 - A325
  • [33] Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis
    Zhu, Chuan
    Wang, Guowei
    Li, Jinqing
    Chen, Li
    Wang, Chaoli
    Wang, Yajie
    Lin, Ping
    Ran, Hong
    NEUROLOGICAL RESEARCH, 2014, 36 (11) : 1028 - 1034
  • [34] Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-Controlled Studies (vol 36, pg 1130, 2014)
    Lehrke, M.
    CLINICAL THERAPEUTICS, 2014, 36 (11) : 1705 - 1705
  • [35] Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension
    Philipp, Thomas
    Smith, Timothy R.
    Glazer, Robert
    Wernsing, Margaret
    Yen, Joseph
    Jin, James
    Schneider, Helmut
    Pospiech, Rainer
    CLINICAL THERAPEUTICS, 2007, 29 (04) : 563 - 580
  • [36] Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers
    Erpenbeck, Veit J.
    Vets, Eva
    Gheyle, Lien
    Osuntokun, Wande
    Larbig, Michael
    Neelakantham, Srikanth
    Sandham, David
    Dubois, Gerald
    Elbast, Walid
    Goldsmith, Paul
    Weiss, Markus
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (04): : 306 - 313
  • [37] A phase 2, 36-week, open-label, follow-up study assessing the long-term safety and efficacy of the adenosine A2A receptor antagonist preladenant in subjects with Parkinson's disease and motor fluctuations
    Wolski, K.
    Factor, S. A.
    Togasaki, D. M.
    Huyck, S.
    Cantillon, M.
    Ho, T.
    MOVEMENT DISORDERS, 2011, 26 : S145 - S145
  • [38] Double-blind, placebo-controlled, dose-ranging study of the safety and tolerability of SIB-1508Y, a nicotinic receptor agonist, in early Parkinson's disease patients
    Blindauer, K
    NEUROLOGY, 2000, 54 (07) : A278 - A278
  • [39] Once-Daily Opicapone Improves OFF-Time in Patients with Parkinson's Disease and Motor Fluctuations: Pooled Subgroup Analysis of Two Randomized, Double-Blind, Placebo-Controlled Studies
    Lew, Mark F.
    Hauser, Robert A.
    Lees, Andrew J.
    Ferreira, Joaquim
    Poewe, Werner
    Rascol, Olivier
    Olson, Kurt
    Farahmand, Khodayar
    Siegert, Scott
    Rocha, Jose-Francisco
    Soares-da-Silva, Patricio
    Liang, Grace S.
    ANNALS OF NEUROLOGY, 2019, 86 : S181 - S182
  • [40] Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
    Ashina, Messoud
    Kudrow, David
    Reuter, Uwe
    Dolezil, David
    Silberstein, Stephen
    Tepper, Stewart J.
    Xue, Fei
    Picard, Hernan
    Zhang, Feng
    Wang, Andrea
    Zhou, Yanchen
    Hong, Frank
    Klatt, Jan
    Mikol, Daniel D.
    CEPHALALGIA, 2019, 39 (14) : 1798 - 1808
12345